Conditions

Subcategories:Axial Spondyloarthritis Clinical Criteria/Guidelines Gout and Crystalline Arthritis Myositis Osteoarthritis and Bone Disorders Other Rheumatic Conditions Pain Syndromes Pediatric Conditions Psoriatic Arthritis Rheumatoid Arthritis Sjögren’s Disease Soft Tissue Pain Systemic Lupus Erythematosus Systemic Sclerosis Vasculitis

Let’s Discuss Part 2: More Insights from the ACR Convergence 2025 Review Course

Jason Liebowitz, MD, FACR | October 28, 2025

The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on cutaneous manifestations of rheumatic diseases, gout, macrophage activation syndrome and vasculitis.

Gout & Cardiometabolic Co-Morbidities

Jason Liebowitz, MD, FACR | October 28, 2025

ACR Convergence 2025 experts explore gout’s deep ties to MetS, insulin resistance and cardiovascular mortality, weighing new data on colchicine, febuxostat and SGLT2 inhibitors.

What’s New in Psoriatic Arthritis?

David Pisetsky, MD, PhD | October 28, 2025

Dr. David Pisetsky curated the research presented at ACR Convergence 2025 and answers the question “What new research on psoriatic arthritis has the potential to impact patient care or future research?”

Let’s Discuss: Insights from the ACR Convergence 2025 Review Course

Jason Liebowitz, MD, FACR | October 27, 2025

The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on SLE and lupus nephritis, inflammatory brain diseases, drug management of rheumatic diseases and mimics of inflammatory myopathies.

Promising Combination Treatment for Gout

Michele B. Kaufman, PharmD, BCGP | October 27, 2025

The FDA has accepted a biologics license application for nano-encapsulated sirolimus with pegylated-adricase (NASP), a combination treatment designed to reduce serum uric acid levels in patients with uncontrolled gout.

Pediatric Rheumatologist with Lupus Models Hope & Resilience for Her Patients

Gretchen Henkel in collaboration with Adaobi Ugochukwu, MD | October 16, 2025

From educating her colleagues to sharing stories of hope & words of encouragement with her patients, pediatric rheumatology resident Adaobi Ugochukwu draws on her own experience with lupus to ensure that patients receive empathetic, compassionate care.

A Liquid Biopsy for Lupus Nephritis?

Samantha C. Shapiro, MD | October 10, 2025

Urine biomarkers have the potential to change how lupus nephritis is managed, serving as a noninvasive means of early detection, assessing treatment response and more.

Study: Reducing Cardiovascular Risks Helps Lupus Patients

Deborah Levenson | October 8, 2025

Long-term remission & control of CVD risk factors can reduce the risk of atherosclerosis in lupus; triple APL positivity raises the risk of CVD, study finds.

What Clinicians Should Know About Midfoot Osteoarthritis

Yvonne M. Golightly, PT, MS, PhD, Jill Halstead, BSc, MSc, PhD, MRCPod, John B. Arnold, PhD, Lara S. Chapman, MSc, BPod, Catherine J. Bowen, PhD, BPod, Marian T. Hannan, DSc, MPH, Hylton B. Menz, PhD, BPod, Kade L. Paterson, PhD, BPod, BAppSci(Hons) & Martin J. Thomas, PhD, MCSP | October 8, 2025

Midfoot OA experts offer an overview of a common, but under-recognized, form of OA, & discuss quality of life impacts, treatments, clinical evaluation procedures & the critical need for further research.

Insights into Mechanisms of Anti-Inflammatory Response to Exercise

Bryn Nelson, PhD | October 8, 2025

A recent Proceedings of the National Academy of Sciences study found that high-intensity aerobic exercise may reduce the release of cell-free DNA & tamp down inflammation over time.